05 August 2024- Illumina announced it has expanded its oncology menu for NovaSeq X Series customers. The company began offering the newly verified high-throughput version of TruSight Oncology 500 (TSO 500 HT), and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), in recent months. These assays enable labs to confidently expand oncology testing research of tissue and liquid biopsy samples, with new transformative sequencing economics, faster sequencing run times, and broader batch sizes on the NovaSeq X Series for the first time.
“We are excited to deliver customers our flagship oncology assays, now fully tested and supported on the NovaSeq X,” said Everett Cunningham, chief commercial officer of Illumina. “Empowering labs to scale distributed comprehensive genomic profiling serves to help advance the use of CGP in clinical oncology research and drive precision oncology forward.”
However, Comprehensive genomic profiling (CGP) assesses hundreds of genes across all variant classes, and immuno-oncology biomarkers, in a single assay from one sample to enable therapy selection research. Professional guidelines in oncology increasingly include CGP.
Laura Knight, global VP of Genomic Services at Almac Diagnostic Services, said: “As a leader in next-generation sequencing diagnostics and research, Almac is delighted that Illumina TSO 500 ctDNAv2 is now being made available on the NovaSeq X Plus platform to enable comprehensive genomic profiling. The NovaSeq X Plus compatibility takes molecular analysis of blood-based biomarkers to new levels.”
Also Read: AbbVie Completes Acquisition of Cerevel Therapeutics
Moreover, TSO 500 ctDNA v2 offers improvements including transformative sequencing economics; faster sequencing run times by about 40%, resulting in a three-day total assay turnaround time; and more sustainable logistics, with ambient temperature shipping for consumables.
“With increased throughput, faster turnaround time, and optimized reagent economics, Almac can now accelerate oncology research and diagnostic development,” Knight added. ” Also We believe that the TSO500 ctDNA v2 assay, combined with the power of NovaSeq X Plus, represents a transformative advancement in precision medicine.”
